Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B virus (HBV) RNA transcripts represent a critical therapeutic target for achieving a functional cure in patients with chronic hepatitis B infection. The HBV genome is highly compact, utilizing four overlapping open reading frames transcribed from covalently closed circular DNA (cccDNA) or integrated viral DNA into multiple overlapping transcripts that share a common 3' polyadenylation signal. Because of this unique overlapping structure, therapeutic agents such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) can target conserved 3' regions to simultaneously degrade all major viral transcripts, including pregenomic RNA (pgRNA) and messenger RNAs encoding HBsAg, HBeAg, and viral polymerase. This degradation halts the production of viral proteins that act as immune tolerogens, thereby suppressing viral replication and potentially restoring the host's innate and adaptive immune responses. Clinical candidates targeting these transcripts, such as bepirovirsen, imdusiran, and elebsiran, have demonstrated significant and sustained reductions in circulating HBsAg levels, offering a promising finite treatment strategy to achieve functional cure.
Degradation of viral transcripts via RNA interference (RNAi) using small interfering RNAs (siRNAs) or RNase H-mediated cleavage using antisense oligonucleotides (ASOs), thereby preventing the translation of viral proteins and inhibiting viral replication.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B virus RNA (HBV RNA).